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Abstract
Background: Increasing resistance to anti-tuberculosis drugs has driven the need for developing new drugs.
Resources such as the tropical disease research (TDR) target database and AssessDrugTarget can help to prioritize
putative drug targets. Hower, these resources do not necessarily map to metabolic pathways and the targets are not
involved in dormancy. In this study, we specifically identify drug resistance pathways to allow known drug resistant
mutations in one target to be offset by inhibiting another enzyme of the same metabolic pathway. One of the putative
targets, Rv1712, was analysed by modelling its three dimensional structure and docking potential inhibitors.
Results: We mapped 18 TB drug resistance gene products to 15 metabolic pathways critical for mycobacterial growth
and latent TB by screening publicly available microarray data. Nine putative targets, Rv1712, Rv2984, Rv2194, Rv1311,
Rv1305, Rv2195, Rv1622c, Rv1456c and Rv2421c, were found to be essential, to lack a close human homolog, and to
share >67 % sequence identity and >87 % query coverage with mycobacterial orthologs. A structural model was
generated for Rv1712, subjected to molecular dynamic simulation, and identified 10 compounds with affinities better
than that for the ligand cytidine-5′-monophosphate (C5P). Each compound formed more interactions with the protein
than C5P.
Conclusions: We focused on metabolic pathways associated with bacterial drug resistance and proteins unique to
pathogenic bacteria to identify novel putative drug targets. The ten compounds identified in this study should be
considered for experimental studies to validate their potential as inhibitors of Rv1712.
Background
Mycobacterium tuberculosis, the causative agent of tu-
berculosis (TB), is responsible for around two million
deaths and nine million new cases annually. South Africa
(SA) is one of the worst affected TB countries [1] and
was an epicentre for an HIV-associated, extensively
drug-resistant TB (XDR-TB) outbreak in 2005 within the
KwaZulu Natal (KZN) province [2]. Three M.tubercu-
losis strains were subsequently isolated from sputum of
HIV co-infected patients from KZN. These strains repre-
sent three levels of varying drug resistance phenotypes
namely; susceptible, multiple drug resistant (MDR) and
XDR TB [3].
Generally, TB strains are classified as MDR if they are
resistant to first-line drugs Isonaizid (INH) and Rifampi-
cin (RIF), and as XDR if they are additionally resistant to
one of the second-line injec drugs Capreomycin, Kana-
mycin or Amikacin and at least one fluoroquinolone
drug [1]. Increasing resistance to anti-TB drugs means
that the need for novel drugs is growing in urgency.
Current anti-TB drugs target information-processing
DNA and RNA polymerase or DNA gyrase [4]. Drugs
could, however, alternatively target metabolic pathways
unique to this pathogen by comparing host and patho-
gen metabolism [5, 6]. The tropical disease research
(TDR) target database and AssessDrugTarget can help in
prioritizing putative drug targets by assigning a set of
weighted criteria [7, 8], though most of these targets do
not map to metabolic pathways and are not involved in
dormancy. In this study, we specifically identify drug re-
sistance pathways to allow known drug resistant
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mutations in one target to be offset by inhibiting another
enzyme of the same metabolic pathway. Putative targets
were filtered to exclude non-viable candidates based on
essentiality for survival, lack of homology to human
host, known biological function and conserved between
mycobacterial species (Fig. 1). One of the proposed tar-
gets, Rv1712 was analyzed by Caceres et al. [9]. However,
the authors did not deposit their homology models. Fur-
thermore, their MD simulations were insufficient at 3 ns.
The published homology modeling data for Rv1712 in the
absence of any experimental data was insufficient as a
starting point for identifying potential inhibitors. In this
study, Rv1712 was screened for potential inhibitors using
a strategy that included molecular modeling, molecular
dynamics and in silico docking of potential inhibitors.
Results
Genome comparisons and pathway analysis
Genomic data from different TB strains previously con-
firmed ten point mutations in eight genes involved in
first and second-line drug resistance and computation-
ally identified 26 novel mutations in 20 genes in MDR
and XDR KZN strains (https://www.broadinstitute.org).
Further literature searches identified ten genes linked to
resistance to first and second-line anti-TB drugs [10]. In
this study, we exclusively focussed on the 18 experimen-
tally verified drug resistance genes. Using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database
[11], twelve of the resulting 18 gene products linked to
drug-resistance were mapped to 15 metabolic pathways,
while six could not be assigned to a KEGG pathway
(Additional file 1: Table S1). Three of the pathways, pyr-
imidine (42 genes), oxidative phosphorylation (47 genes),
and nicotinate and nicotinamide metabolism (16 genes)
were selected for their functional importance to bacterial
growth and the latent state [12–15] as well as their
promise as targets in slow growing bacteria [12–15].
Selection and prioritization of candidate genes
Of 105 gene products in the three selected pathways, 14
are known TB drug targets and were excluded from fur-
ther analyses [10]. The remaining 91 genes were checked
to avoid duplication of research efforts with the TB Struc-
tural Genome Consortium (TBSGC) [16] leaving 38 puta-
tive targets. Additionally, no crystal structure was available
for the TBSGC-target Rv2984 and was therefore included
in our analysis (Additional file 2: Table S2). Of these 39
targets, 17 are essential for M. tuberculosis survival based
on a Rv number query search within the Tuberculist Web
server, have known biological function and have no ex-
perimental 3D structure (Additional file 2: Table S2).
Of these, nine are not homologous to any human pro-
teins (p < 0.0001). They share >67 % sequence identity
identity and >82 % sequence coverage with orthologs
from other mycobacterial species (Additional file 3:
Table S3). Publicly available microarray data indicates
Fig. 1 A workflow illustrating the different steps taken to identify potential drug targets for M. tuberculosis, homology modeling, molecular
dynamics, docking strategy and interaction analysis for one target Rv1712
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that four of the nine genes, Rv1712, Rv2984, Rv1622c and
Rv2421c, are up-regulated during dormancy (starvation,
hypoxia and oleic acid, p-values between 0.02 and 10−9)
while five, Rv2194, Rv1305, Rv1456c, Rv2195 and Rv1311,
are weakly down-regulated (p < 0.01). Other analyses used
to validate the selected targets included BLASTp searches
against three species of human gut flora bacteria
(Staphylococcus aereus, Enterococcus faecalis and Escheri-
chia coli) and mouse proteins (Mus musculus), revealing
no homology to any mouse proteins (Additional file 4:
Table S4). However, six proteins showed varying degrees
of sequence identity and coverage to some intestinal bac-
teria. Of the nine proteins, Rv1712, Rv1311 and Rv2421c
share ~40 % sequence identity and 90 % sequence cover-
age to orthologs in all three intestinal bacteria, while
Rv2984 and Rv1622c share 30–40 % sequence identity to
orthologs in two bacteria, and Rv1305 is 55 % identical to
an ortholog in host gut bacteria with 87 % sequence cover-
age (Additional file 4: Table S4). The three remaining pro-
teins, Rv2194, Rv2195 and Rv1456c are without homologs
in the three human gut bacteria (Additional file 4: Table
S4). KEGG pathway maps for the nine gene products were
generated using the M. tuberculosis H37Rv strain database
(Additional file 5: Figure S1, Additional file 6: Figure S2
and Additional file 7: Figure S3). Interestingly, Rv1622c
and Rv1456c are at the interface of two metabolic path-
ways (Additional file 8: Table S5).
Template selection and model building
A search of the protein data bank (PDB) revealed 1Q3T,
2H92, 1CKE and 1KDO as homologs for Rv1712. An
alignment of the five proteins indicated sequence iden-
tities of 43 % (1Q3T), 40 % (2H92), 39 % (1CKE) and
40 % (1KDO) making them useful modeling templates.
Incorporating structural data reveals a P-loop (residues
10–16) in the N-terminal ATP-binding domain and resi-
dues in a nucleoside monophosphate (NMP) binding site
to be highly conserved. The conserved active site resi-
dues shared by Rv1712 and its four templates potentially
allows these residues to be used in identifying novel in-
hibitors for enzymes of Rv1712 in docking studies.
Fifty structural models were constructed for Rv1712
and the model with the lowest discrete optimised pro-
tein energy (DOPE) score was selected for further ana-
lysis. The fold assessment score GA341 for the lowest
DOPE model was equal to 1.0 suggesting that the cor-
rect fold was assigned to the protein Rv1712. The
Rv1712 structural model contains nine α-helices and eight
β-strands and encompasses a CORE (residues 10–16), an
NMP-binding (33–100) and a LID (155–168) domain
(Fig. 2). The NMP-binding domain is free to rotate during
substrate binding and presumably recognizes both CMP
or dCMP.
Model quality validation
The DOPE score profile of the Rv1712 model is similar
to that of templates 1Q3T, 1CKE, 1KDO and 2H92
(Additional file 9: Figure S4). Without high energy regions,
the model would appear to be native like. The normalised
DOPE Z-score was −0.77 indicating high model reliability.
The model also conforms to permitted stereochemical re-
straints with 91.6 % of residues in most favoured and none
in disallowed regions of the Ramachandran plot [17]. The
quality factor calculated using the protein structure verifi-
cation algorithm implemented in ERRAT [18] indicates
that 85 % of residues in the 3D model have a low error rate
compared to crystal structures of the same size and length.
A Prosa Z-score for the Rv1712 model of −7.67 is compar-
able to those of the templates (−7.31 to −7.85). The root
mean square deviation (RMSD) values obtained after align-
ing all atoms suggest that the Rv1712 model is most simi-
lar to 2H92 (0.53 Å) and 2O8R (0.62 Å) than to 1Q3T
(3.25 Å) and 1CKE (2.33 Å). This indicates very little devi-
ation from the main chain carbon atoms between target
and template(s) suggesting homology and similarity be-
tween the structures. The inclusion of the recently solved
crystal structure of cytidylate kinase from M. smegmatis
did not significantly alter the Rv1712 model (Additional
file 10: Figure S5). The Rv1712 model thus suitably
approximates the actual protein structure (Fig. 2).
Fig. 2 Ribbon diagram of the structural model of M. tuberculosis
cytidilate monokinase (Rv1712). The CORE domain, NMP-binding
domain and the LID domain are labelled as well as ligands CMP
and SO4 shown as sticks. Figure generated using PyMOL [45]
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Molecular dynamics
Trajectory analysis of the Rv1712 model in complex
with ligand cytidine-5′-monophosphate (C5P) results in
a rapid increase in RMSD during the first 2500 ps
followed by a gradual decrease after 5000 ps for both
the protein backbone atoms and ligand C5P carbon
atoms (Additional file 11: Figure S6). The ligand RMSD
was measured by performing a least squared fit to the
starting conformation while allowing translation and ro-
tation of all bonds within the ligand. An equilibrium
phase was reached within 5000 ps suggesting that 30 ns
was sufficient for stabilizing the structure. The average
total energy and the potential energy reaches conver-
gence at −1.1 × 106 and −1.4 × 106 KJ/Mole, respectively
(Additional file 12: Figure S7). The RMS fluctuation for
the C-alpha residues ranged between 0.07 and 0.38 nm
and the radius of gyration for the molecule stabilized
after 5000 ps fluctuating between 1.75 and 1.8 nm
(Additional file 13: Figure S8 and Additional file 14:
Figure S9). The simulation was repeated at random
seed allowing all atoms to reach 300 K temperature
and no significant drift was observed between the two
trajectories.
Virtual compound screening and interaction analysis
The lowest energy conformation obtained for docking
C5P to the equilibrated structure was −7.3 kcal/mol
(Additional file 15: Table S6). Screening 48 compounds
from the ZINC database against the equilibrated struc-
ture yielded ten compounds with higher binding affinity
values than −7.3 kcal/mol (Additional file 15: Table S6).
Interaction analysis using PoseView shows that the nat-
ural substrate C5P forms one hydrogen bond with glu-
tamine113 and a п-stacking interaction with tyrosine36.
Salt bridge interaction analysis confirmed one positively
charged residue arginine37 of Rv1712 with negatively
charged C5P phosphate group. Compounds 03869482,
09007749, 04536469, 01785780, 04096023, 01532581,
03861744, 13431062, 08952080 and 03869816 respect-
ively form 2, 6, 4, 5, 4, 4, 4, 7, 2 and 4 hydrogen bonds
to Rv1712 (Fig. 3A and B). BINANA interaction analysis
indicates a salt bridge between each compound and posi-
tively charged residues of Rv1712 such as lysine14, argin-
ine37, aspartate129 and arginine185 (Additional file 15:
Table S6). All compounds similarly retain a п-stacking
interaction with tyrosine36 of Rv1712 (Additional file 15:
Table S6).
Discussion
This study focuses on metabolic pathways previously tar-
geted by anti-TB drugs to increase the likelihood of
selecting effective targets. Target validation included five
filtering steps and two quality tests. Previous studies
used AssessDrugTarget and the TDR target database to
identify potential drug targets in pathogenic bacteria. This
led to the transcription factor DevR and the enzymes
GlnE and FbpD to be proposed as potential drug targets
[7] based on their high ranking on the metabolic list des-
pite neither being part of a metabolic pathway. The target
protein FbpD was, moreover, listed among other essential
enzymes in the M. tuberculosis species-specific list al-
though not being an essential enzyme. Similarly, the bio-
logical role of the enzymes GlnE and FbpD remain
unknown, limiting their use for biochemical and biophys-
ical assays [19]. Our approach improves on these methods
by selecting essential enzymes which have been function-
ally characterised thereby increasing the likelihood of
selecting effective putative target candidates.
Predicted sub-cellular localization of putative targets
Of the identified putative targets, six (Rv2984, Rv2194,
Rv1305, Rv1622c, Rv2195, Rv1456c) are cytoplasmically
membrane-associated proteins whereas three, Rv1712,
Rv1311 and Rv2421c, are bone fide soluble, cytoplasmic
proteins [20]. Membrane proteins are preferred drug tar-
gets as they are accessible from their extracellular surface
without the drug having to be taken up or modified [21].
Unfortunately, membrane proteins are far more difficult
to analyse structurally than soluble proteins hindering the
assessment of their druggability [22]. Drug delivery strat-
egies to intracellular targets have improved over the years
and include the use of cell penetrating peptides, pH re-
sponsive carriers and endosome-disrupting agents [21].
Cytidylate kinase and polyphosphate kinase as drug
targets
Of the nine putative targets obtained using our ap-
proach, six (Rv1712, Rv2984, Rv2194, Rv1311, Rv1305
and Rv1622c) were previously identified as potential
drug targets [4], underlining the robustness of our
method. Of these, only Rv1712, cytidylate kinase, and
Rv2984, polyphosphate kinase, have been investigated
both experimentally and computationally [9, 23]. Two
studies of polyphosphate kinase experimentally support
polyphosphate kinase as a promising drug target [23, 24]
while a study of cytidylate kinase did not publically de-
posit the predicted model structure and no inhibitors
were been identified [9]. Supported by our findings, cyti-
dylate and polyphosphate kinase would thus appear to
be relevant M. tuberculosis drug targets. The three
remaining proteins from our study, Rv2195, Rv1456c
and Rv2421c have, to our knowledge, not previously
been proposed as drug targets.
Pathway and drug target validation
The nine genes reported in this study form part of three
metabolic pathways: pyrimidine, oxidative phosphoryl-
ation, nicotinate and nicotinamide metabolism. Of these,
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Rv1622c and Rv1456c constitute a two component
system unique to bacteria, fungi and plants. Drugs
inhibiting these targets would therefore be specific to
bacteria with minimal human toxicity. The target
Rv1712 is central to the phosphorylation of ATP to
nucleoside diphosphates in the pyrimidine pathway
[25]. The known TB drug target Rv0667 forms part
of the purine and pyrimidine pathway and mutations
in its gene rpoB lead to RIF resistance. With Rv1712
sharing this pathway it could be an attractive alterna-
tive target to inhibit the pathway.
Five candidates, Rv2984, Rv2194, Rv1311, Rv1305 and
Rv2195, map to the oxidative phosphorylation pathway.
The target Rv1854c (gene ndh) in this pathway is the
target for INH and several mutations in this gene ac-
count for INH resistant cases [10, 26]. Inhibiting any of
the five proposed targets could disrupt the pathway and
eliminate M. tuberculosis by reducing its limited ATP
availability during dormancy [14].
Rv2421c transfers phosphorous groups in nicotinate/
nicotinamide salvage and de novo synthesis. Rv2043c of
this pathway is the target of the highly effective drug
PZA that kills persistent bacilli in the initial phase of TB
therapy [27]. Mutations in the encoding gene pncA con-
fer resistance to PZA [28]. Successful inhibition of
Rv2421c could thus help to eradicate slowly growing
persistent bacilli in TB infection.
Although the three selected pathways are also found
in humans, the proposed targets are unique to bacteria
and unrelated to human proteins meaning that possible
drugs are unlikely to affect human metabolism. The
similar absence of murine homologs could further allow
for mouse infection studies. The nine targets are con-
served in several mycobacteria pathogenic to humans
such as M. leprae, abscessus, and ulcerans, implying that
broad spectrum inhibitors are possible. As the targets
are also conserved in H. pylori, N. meningitidis and E.
coli, new TB drugs could be used to target these
Fig. 3 a Interactions between the top ranked compounds and active site residues of Rv1712. Panel a shows that the compound 03869482 is
displaying two hydrogen bond interactions. Panel b shows that the compound 09007749 is displaying six hydrogen bond interactions. Panel c
shows that the compound 04536469 is displaying four hydrogen bond interactions. Panel d shows that the compound 01785780 is displaying
five hydrogen bond interactions. Panel e shows that the compound 04096023 is displaying four hydrogen bond interactions. The dashed lines
represents hydrogen bonds. Figures generated using PoseView [50]. b Interactions between the top ranked compounds and active site residues
of Rv1712. Panel a shows that the compound 01532581 is displaying two hydrogen bond interactions. Panel b shows that the compound
03861744 is displaying six hydrogen bond interactions. Panel c shows that the compound 13431062 is displaying four hydrogen bond
interactions. Panel d shows that the compound 08952080 is displaying five hydrogen bond interactions. Panel e shows that the compound
03869816 is displaying four hydrogen bond interactions. The dashed lines represents hydrogen bonds. Figures generated using PoseView [50]
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pathogens. The conservation of the targets underscores
their essentiality and could imply some innate resistance
to mutation. The proteins Rv2194, Rv2195 and Rv1456c
lack close homologs in several human gut bacteria mean-
ing that their inhibition by drugs is unlikely to disrupt the
host microbiome. Although Rv1712, Rv2984, Rv1311,
Rv1305, Rv1622c and Rv2421c share remote homologs in
several gut bacteria, their investigation is warranted as the
target for the TB drug Rifampicin, DNA-directed RNA
polymerase, is highly conserved across all species. A mere
five exchanged residues between eukaryotic and bacterial
RNA polymerase gives rise to the selectivity of RIF [29].
While Rv1305 satisfied all our prioritization criteria, its
conservation in humans demote it in our list of putative
targets. Subtle differences between bacterial and human
versions could nevertheless reinstate it Rv1305 as a poten-
tial target. Finally, Rv1712 was further analysed because
our results and experimental findings indicate it to be es-
sential for M. tuberculosis [13].
Molecular dynamics
The simulated molecular dynamics of Rv1712 in complex
with C5P indicated 30 ns to be sufficient for reaching a sta-
bility plateau. This is in contrast to the [9] study which
found 3 ns to be sufficient for equilibrating the structure.
However, the RMSF fluctuation of all C-alpha residues for
our model was similar to that of the [9] study suggesting
that the presence of ligand C5P introduces major stability
of the LID domain (residues 155–168) of the protein pre-
venting ATP hydrolysis. Additionally, the radius of gyration
for the molecule became constant after 5000 ps suggesting
that the Rv1712-C5P complex has a stable surface struc-
ture suitable for virtual screening and drug design.
Virtual screening and interaction analysis
Computational methods have proven useful in the past to
identify novel drugs to treat resistant strains of Mycobac-
terium tuberculosis [30]. Using similar approaches we have
successfully identified ten compounds with higher binding
affinity values compared to C5P docked to the equili-
brated model of Rv1712. Analysis of these ten compounds
showed a larger number of interactions namely hydrogen
bonds and salt bridges compared to ligand C5P suggesting
a stronger affinity for Rv1712. Further analysis revealed
interaction of compounds with highly conserved key resi-
dues (Thr32, Gly33, Tyr36, Arg37, Asp129 and Arg185) im-
portant for catalytic activity of Rv1712 as identified in a
study by [31] using the homologous template 2H92. Inter-
estingly our compounds also interact with Lys14 which is
part of the P-loop forming the large anion hole which usu-
ally binds the sulphate ion thereby preventing nucleophillic
attack by the phosphate of ATP. This implies a role for
these compounds as competitive inhibitors of Rv1712. Al-
though ligand C5P makes only one hydrogen bond with
residue Gln113 in our predicted model compared to the [9]
study which makes ten hydrogen bonds, this is only due to
a lower hydrogen bond cut-off value (>2.4 Å). Nine com-
pounds share the overall orientation of C5P and its binding
site. The evidence provided advocates the need for add-
itional in silico studies to validate these compounds as in-
hibitors of Rv1712. We propose that the compounds
should be tested experimentally to establish their non-
toxicity to human cell lines and their inhibition ofM. tuber-
culosis growth.
Conclusions
In this study, known drug resistance genes were mapped
to three KEGG metabolic pathways. All proteins from
these three metabolic pathways were subjected to a filter-
ing criteria such as essentiality, known function, absence of
human homologs and conservation within Mycobacteria.
This resulted in the identification of nine putative drug tar-
get candidates of which three are novel (Rv2195, Rv2421c
and Rv1456c) The integrated approach successfully imple-
mented in this study can be extended to other pathogenic
organisms for which drug resistance data is available. Fur-
thermore, ten compounds with higher affinity than sub-
strate C5P was identified using molecular docking and
these compounds warrants further investigation to assess
their potential to inhibit M. tuberculosis growth.
Methods
Identification of potential M. tuberculosis targets
A comparison of the genomes of three KwaZulu-Natal
TB strains, KZN 4207, KZN 1435 and KZN 605, identi-
fied ten mutations in eight genes that account for drug
resistance and another 26 coding and non-coding poly-
morphisms in 20 further genes for differences between
MDR and XDR strains [3]. We investigated the latter set
of 20 proteins with respect to their metabolic pathways.
Most (75 %) could not be assigned to any pathway and
40 % are annotated as hypothetical proteins. Only two
genes map to protein transport and transcription. Ten
additional genes associated with first and second-line TB
drug resistance were identified from the literature. This
study focuses on 18 essential genes associated with drug
resistance [10].
Metabolic pathway analysis and target prioritization
The 18 known drug resistance genes identifiers namely
the Rv numbers were used to query the KEGG M. tuber-
culosis H37Rv strain database [11]. The Rv numbers
were used as input to search the KEGG database which
returned metabolic pathway diagrams showing the loca-
tion of the specific target. We then extracted all the gene
products by Rv number which provided us an opportun-
ity to investigate other genes (excluding known genes) as
drug candidates. Six of the 18 drug resistance genes have
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not been annotated with any pathway data and were
assigned to what is called “pathway holes”. We therefore
focused on targets that map to pathways containing
first-line drug resistance genes as these pathways have
been extensively characterized [32]. Three metabolic
pathways were selected because of experimental evi-
dence for gene products within these pathways associ-
ated with importance for bacterial growth during active
and latent states and their potential for developing anti-
microbial agents for other genes within these pathways
[12–15]. These three pathways comprise 105 genes of
which 14 are known TB genes that were excluded from
our search for drug targets. Thirty-eight of the
remaining 91 H37rV genes were not currently under in-
vestigation by the TB Structural Genome Consortium
(TBSGC) as reported on the TBSGC web portal. Only
one target currently being investigated by the TBSGC
was included in our candidate list because no structure
has yet been elucidated for this protein.
The TubercuList World Wide Web Server [33] was
used to query the combined 39 genes based on their Rv
number to find relevant information regarding essential-
ity of the gene, if its function is known (meaning it has a
biological role within an reaction step of the pathway)
and if a 3D structure is known. TubercuList provided
valuable experimental evidence for growth based on
transposon site hybridisation assays [13, 34] and other
mutagenic studies done on all M. tuberculosis genes
confirming their essentiality or non-essentiality. Seven-
teen of the 39 potential drug targets can be classified as
essential genes with known biological function and were
used for BLASTp searches against the Homo sapiens
database at NCBI (build GRCh37/hg19) [35]. Among
these 17 proteins, nine showed no similarity to human
proteins and were chosen as potential drug targets, elim-
inating possible human host protein-drug interactions
(expectation score <0.0005). The amino acid sequence of
each of the nine selected drug candidates were used to
perform a BLASTp search against 24 Mycobacterium
species to determine inter-species sequence conservation
(Additional file 4: Table S4). A high degree of sequence
conservation suggests that mutations in these proteins
are not tolerated thereby prohibiting the spontaneous
occurrence of drug resistance. The M. tuberculosis targets
that were retained were investigated for their possible role
in M. tuberculosis survival during latency conditions.
Genes that are essential for dormancy survival are up-
regulated during latent conditions of M. tuberculosis and
should be targeted in an attempt to combat TB persist-
ence. The M. tuberculosis protein accession numbers were
used to query the Tuberculosis Database [36] to obtain
gene expression data collated for each target. These in-
clude samples, conditions and the statistically significant
measurements (p-value) for each experiment. Conditions
most often associated with persistence have been reported
as hypoxia, starvation and change in PH [37]. Additionally,
the lack of close homologs to human gut flora would facili-
tate the design of M. tuberculosis specific drugs and inform
in vivo mouse infection studies. To this end, protein
BLAST searches were carried out against three species of
human gut flora bacteria Staphylococcus aereus (taxid:
1280), Enterococcus faecalis (taxid: 1351) and Escherichia
Coli (taxid: 562) and mouse proteins (Mus musculus).
Homology modeling
Homology models were constructed for M. tuberculosis
cytidylate kinase, Rv1712, using MODELLER version 9.7
[38]. Homologous template structures were identified by
amino-acid sequence alignment against those of the Protein
Data Bank (PDB) [39] using the profile.build module of
MODELLER. Multiple sequence alignments were obtained
using the salign routine. The manually optimized alignment
was used by MODELLER model-mult-hetero module to
construct the models based on satisfaction of spatial re-
straints. Structural templates for Rv1712 were cytidine
monophosphate kinase (CMPK) from Streptococcus pneu-
moniae (1Q3T), cytidylate kinase from Staphylococcus aur-
eus in complex with cytidine-5-monophosphate (2H92),
and CMPK from E. coli both without (1CKE) and with C5P
(1KDO). We randomly generated fifty models for Rv1712
using MODELLER in the presence of ligand C5P.
Model evaluation
The lowest Dope score model (LDSM) was selected for
qualitative analysis as it presumably is closest to the native
protein structure [40]. The discrete optimized protein en-
ergy (DOPE) score energy profiles were calculated using
evaluate_model.py for the LDSM and the templates and
compared graphically using Gnuplot (version 4.2) to lo-
cate regions of high energy [41]. The quality of the LDSM
was assessed using the normalised DOPE Z-scores
(average score of all the heavy C-alpha atom pairs)
calculated using assess_normalised_dope.py with DOPE
Z-scores below −1 indicating acceptable models. The reli-
ability of regions involved in substrate binding were
assessed using PROSAII [42] which indicates overall
model quality (Z-score) and measures the deviation of the
total energy of the structure with respect to an energy dis-
tribution derived from random conformations [43, 44]
while the stereochemical quality was checked using PRO-
CHECK [17]. The quality of the LDSM with respect to
non-bonded atom-atom interactions was assed using
ERRAT [18]. Finally, the structural similarity of model and
the four templates were assessed using root mean square
deviations (rmsd) as calculated in PyMol [45] by aligning
all atoms to one another.
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Molecular dynamics
The LDSM was energy minimized by 1000 steps of stee-
pest descent and 5000 steps of conjugated gradients using
GROMACS. The energy minimized structure was then
subjected to 30 ns of molecular dynamics simulation to
determine stability of the structure in complex with ligand
C5P also in GROMACS [46]. The simulation was repeated
using random numbers for generating velocities to valid-
ate the reproducibility of the results verifying that all ob-
servables including the trajectory converge to reach their
equilibrium values. The total and potential energy terms
were calculated using GROMACS tool g_energy. Also, the
backbone atoms RMSD and C-alpha atoms RMSF values
was calculated using GROMACS utilities g_rms and
g_rmsf for the equilibrated structure over the whole tra-
jectory. RMSF is a measure of deviation between the pos-
ition of a particle and some reference position averaged
over time. The radius of gyration was calculated for all
backbone atoms using GROMACS utility g_gyrate.
Parameter optimisation
The ligand C5P was docked to the equilibrated model of
Rv1712’s active site; Asp31, Tyr36, Arg37, Arg106,
Arg128, Asp129, Arg178, Asp182 and Arg185 using
AutoDock-vina. Vina implements a sophisticated gradient
optimisation method in its local optimisation step and an
pairwise empirical scoring function to find the global en-
ergy minimum conformation of a ligand. Vina was se-
lected for rigid body docking because it has been validated
for its accuracy in reproducing experimental conforma-
tions. The top ten binding modes produced by the dock-
ing run of the ligand C5P were compared to the most
stable ligand trajectory by visualizing the output file and
input structure in Pymol. This was done to determine if
AutoDock-vina correctly predicted the top binding con-
formation of the ligand as the most energy favourable and
if it can replicate the most stable ligand trajectory in silico.
Molecular docking
Docking C5P to the equilibrated structure
The equilibrated protein structure Rv1712.gro was con-
verted to pdb format by editconf and sodium atoms, solv-
ent and C5P molecules were deleted because no optimal
force field has been defined for these molecules. The final
Rv1712 model and C5P were converted to a set of united-
atom aliphatic carbons (force field where all hydrogens on
aliphatic carbons are united with carbons), aromatic car-
bons, polar hydrogens, hydrogen bonding nitrogens and
oxygens with charges called pdbqt using AutoDock Tools
[47] to correct for errors such as missing atoms, added
H2O, more than one molecule chain breaks instead of one,
and alternate locations of rotamers for side chains. The re-
ceptor’s binding site was kept fixed while seven bonds
within the ligand was treated as rotatable. Binding
energies were calculated and the docked ligand pose was
visualised using Pymol. The binding energies reported
represent the sum of the intermolecular energy, total in-
ternal energy and torsional free energy minus the energy
of the unbound system.
Compound screening and interaction analysis
The ZINC database was searched using the simple molecu-
lar input line entry (SMILE) format of ligand C5P imple-
menting an axonpath fingerprint search to identify
structurally similar compounds. After screening, 48 com-
pounds were identified at 95 % structural similarity and
downloaded in sdf format from the ZINC database. The
compounds were converted to pdbqt format using Open
Babel [48] in preparation for docking simulation. The proc-
essed compounds were docked to the overall simulated
protein model of Rv1712 using AutoDock Vina software
[49]. Rigid body docking was performed to obtain several
possible conformations and orientations for the compounds
docked at the receptor’s active site. The Grid box dimen-
sions of previously parameter optimised dockings were im-
plemented. Docking energies calculated during the run
were extracted and ranked using an python script called
vina_screen_get_top.py with lowest energy values at the
top. The top ten lowest energy binding modes for each com-
pound were visually inspected in PyMol and were further
analysed using PoseView and BINANA programs [50, 51].
PoseView determines four types of interactions namely; i)
hydrogen bonds, ii) hydrophobic, iii) metal interactions and
iv) π interactions, while BINANA was used to calculate all
the afore mentioned interactions as well as salt bridges be-
cause this functionality was not present in PoseView.
Availability of supporting data
The scripts, simulation data and docking data for ten
compounds used in these analyses are available on the
South African National Bioinformatics Institute perman-
ent data archive (ftp://ftp.sanbi.ac.za/tb_targets/Rv1712).
All other supporting data are included as additional files.
Additional files
Additional file 1: Table S1. KEGG pathways for genes known to be
associated with 1st and 2nd line drug resistance. The 10 mutations (eight
genes) indicated in bold were verified by the BROAD institute, while the
remainder were identified from literature. Abbreviations used: A-Adenine,
Ala-Alanine, Arg-Arginine, Asn-Glutamine, Asp-Aspartate, Gly-Glycine,
His-Histidine, indel-insertion deletion, Ileu-Isoleucine, Leu-Leucine,
Met-Methionine, N.A-Not available, Pro-Proline, Ser-Serine, T-Thymidine,
Thr-Threonine, Tyr-Tyrosine, Val-Valine. (PDF 143 kb)
Additional file 2: Table S2. Criteria used to filter high priority
M.tuberculosis drug targets. The genes highlighted in bold satisfied all the
selection criteria. The hyphen (−) indicates exclusion from further analysis.
Abbreviations used: NUI- Not under investigation, PDB- Protein Data Bank,
TBSGC- TB Structural Genome Consortium. References 12-Sassetti et al., 2003;
34-Lamichhane et al., 2003. Data can be viewed in Microsoft excel. (XLS 12 kb)
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Additional file 3: Table S3. The 24 sequenced Mycobacterium strains.
Data can be viewed in Microsoft excel. (XLS 34 kb)
Additional file 4: Table S4. Blast hits obtained for Rv1712, Rv2984, Rv2194,
Rv1311, Rv1305, Rv2195, Rv1622c, Rv1456c and Rv2421c against three host
intestinal bacteria. Bacterial species highlighted in bold showed homology to
the query gene. Data can be viewed in Microsoft excel. (XLS 13 kb)
Additional file 5: Figure S1. KEGG metabolic pathway map for
Nucleotide metabolism (pyrimidine metabolism) in M. tuberculosis
H37rV strain. Rv1712 or cmk selected for investigation is shown in red
highlighted boxes and involved in step 2.7.4.14 of this specific pathway.
Known drug resistance gene Rv0667 or rpoB is shown in blue highlighted
box and involved in step 2.7.7.6 of this pathway. M. tuberculosis specific
genes are coloured in green. (PDF 111 kb)
Additional file 6: Figure S2. KEGG metabolic pathway map for Oxidative
phosphorylation in M. tuberculosis H37rV strain. Rv2984 or ppk selected for
investigation is shown in blue highlighted box and involved in step 2.7.4.1
of this specific pathway. Rv2194 or qcrC selected for investigation is shown
in the red highlighted box. Both Rv1305 (atpE) and Rv1311 (atpC) selected
for investigation are shown in brown highlighted box and involved in step
3.6.3.14 of this specific pathway. Rv2195 or qcrA selected for investigation is
shown in the yellow highlighted box involved in cytochrome C reductase.
Rv1456c or COX15 selected for investigation is shown in the magenta
highlighted box involved in cytochrome C oxidase. Rv1622c or CydB
selected for investigation is shown in the light blue highlighted box
involved in cytochrome C oxidase. Known drug resistance gene Rv1854c or
ndh is shown in orange highlighted box and involved in step 1.6.99.3 of this
pathway. M. tuberculosis specific genes are coloured in green. (PDF 157 kb)
Additional file 7: Figure S3. KEGG metabolic pathway map for
Nicotinate and Nicotinamide metabolism in M. tuberculosis H37rV strain.
Rv2421c or nadD selected for investigation is shown in red highlighted
box and involved in step 2.7.7.18 of this specific pathway. Known drug
resistance gene Rv2043c or pncA is shown in blue highlighted box and
involved in step 3.5.1.19 of this pathway. M. tuberculosis specific genes
are coloured in green. (PDF 106 kb)
Additional file 8: Table S5. KEGG pathway descriptors for M.
tuberculosis genes retained after prioritization. Data can be viewed in
Microsoft excel. (XLS 7 kb)
Additional file 9: Figure S4. DOPE score energy profiles graph of the
structural model for Rv1712 (red) and templates 1Q3T (green), 1CKE (dark
blue), 1KDO (light blue) and 2H92 (purple). Generated using Gnuplotv4.2
[41]. (PDF 68 kb)
Additional file 10: Figure S5. RMSD of the backbone atoms of model
Rv1712 (green) and substrate C5P (red) during the 30000 ps simulation.
Generated using Gnuplotv4.2 [41]. (PDF 198 kb)
Additional file 11: Figure S6. The variation in total (green) and
potential energy (red) for the Rv1712-C5P complex during the 30000 ps
simulation. Generated using Gnuplotv4.2 [41]. (PDF 69 kb)
Additional file 12: Figure S7. RMS fluctuations of all Cα residues for
Rv1712 over the 30000 ps simulation. (PDF 55 kb)
Additional file 13: Figure S8. Radius of gyration of all bacbone atoms
for Rv1712 over the 30000 ps simulation. (PDF 29 kb)
Additional file 14: Figure S9. Superimposition of lowest DOPE score
models for the initial and newly generated structures. The blue model
represents the initial model without 3R20 used as a template while the
red model consist of 3R20 used as a template for model construction.
Ligands SO4 and CMP are shown as sticks. RMSD = 0.387 Å. (PDF 33 kb)
Additional file 15: Table S6. Docking scores and number of
interactions for the top ten compounds to Rv1712. The residues
highlighted in bold are conserved catalytic residues while ligand C5P is
highlighted in red. The numbers inside the () indicate the number of
interactions formed between residue and the compound atom. Data can
be viewed in Microsoft excel. (XLS 8 kb)
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